Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and ASCT for Refractory DLBCL
NCT00242996Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2004
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: 2-year Event-Free Survival. Started Mar 2004; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00242996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242996.